Previous 10 | Next 10 |
We have a wide-ranging phone interview with Cassava Sciences' CEO Remi Barbier. He addresses crazy accusations and data safeguards. "Based on the consistency of data and the strength of the science, we are absolutely 100% planning for success." For further details see: I...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The perils of investing in volatile stocks is on full display with Cassava Sciences (NASDAQ: SAVA ). Last month, SAVA stock skyrocketed in price thanks to a positive update on an ongoing issue that’s been putti...
Cassava Sciences (NASDAQ: SAVA) has been embroiled in a controversy for several months related to allegations that it falsified data for its experimental Alzheimer's disease drug simufilam. Last month, the company revealed that it's the subject of a federal investigation. In th...
Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock. Four characteristics to look for are intellectual property, founder owners, insider buying, and the maligned. F...
Cassava Sciences may have removed an outlier from a previous trial in order to improve results. The company's drug simufilam is likely a zinc chelator; the removal of zinc has some beneficial effects for Alzheimer's patients in part because it inhibits oxidation and nitration. Dru...
In my previous article, questions were raised about differences between in vitro and in vivid experimental results, and early-onset and late-onset Alzheimer’s. I address these challenging questions using Eli Lilly’s gamma-secretase inhibitor which failed to slow the pace...
SAVA's recent release of data from its phase 2, open-label extension trial did not satisfy the critics. SAVA has an opportunity in the future to silence any critics with data from phase 3 trials, two of which were initiated recently. I take a look at these trials and the potential...
The journal Neuroscience is considering publishing an expression of concern for a 2005 paper it published from researchers tied to Pain Sciences, the prior name of Cassava Sciences (SAVA +0.1%). The paper concerns the use of ultra-low-dose naloxone. Retraction Watch says that Juan Lerma, the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market is full of ups and downs, which isn’t necessarily a bad thing. Shares of clinical-stage biotechnology company Cassava Sciences (NASDAQ: SAVA ) are prone to peaks and valleys, but this mean...
Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +16%. Kornit (NASDAQ:KRNT) +15%. Aspira...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...